Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adding orally disintegrating selegiline (Zelapar) to patients taking dopamine agonists and experiencing complications

Trial Profile

Adding orally disintegrating selegiline (Zelapar) to patients taking dopamine agonists and experiencing complications

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Selegiline (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 07 Dec 2008 Status changed from recruiting to completed, according to ClinicalTrials.gov.
    • 30 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top